<DOC>
	<DOCNO>NCT01170897</DOCNO>
	<brief_summary>This open-label , multicenter , dose-escalation , safety , tolerability , pharmacokinetic pharmacodynamic study patient advance solid tumor .</brief_summary>
	<brief_title>Study PEGPH20 With Initial Dexamethasone Premedication Given Intravenously Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>A study PEGylated recombinant human hyaluronidase ( PEGPH20 ) administer twice weekly schedule 28 day follow weekly dosing schedule patient advance solid tumor either fail respond standard therapy standard therapy exist .</detailed_description>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Written , sign , IRBapproved inform consent form . Pathologic ( histologic cytologic ) confirmation metastatic locally advanced solid tumor . Patients must pathologically document , definitively diagnose , advance solid tumor refractory standard treatment , standard therapy available patient refuse standard therapy . One tumor measurable RECIST criterion . Karnofsky performance status ≥ 70 % . Ejection fraction ≥ 50 % , determine echocardiogram . Life expectancy least 3 month . Age ≥ 18 year . Acceptable organ function ; normal hepatic , renal hematopoietic function . Negative serum urine pregnancy test result woman childbearing potential . Known brain metastasis . New York Heart Association Class III IV cardiac disease , myocardial infarction within 6 month enrollment , cardiac arrhythmia require medical therapy . Active , uncontrolled bacterial , viral , fungal infection require systemic therapy . Patients uncontrolled diabetes ( require medication change within 30 day screen ) , require insulin therapy . Heparin therapy . Known infection HIV , hepatitis B , hepatitis C. Known allergy hyaluronidase . Women currently breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>PEGPH20</keyword>
	<keyword>PEGylated Recombinant Human Hyaluronidase</keyword>
	<keyword>Metastatic Locally Advanced Solid Tumors</keyword>
</DOC>